Salix Pharmaceuticals receives FDA complete response letter for GIAZO Tablets NDA

Download PDF Copy

Apr 29 2010

Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced the Food and Drug Administration (FDA) has issued a complete response letter regarding the New Drug Application (NDA) for GIAZO™ (balsalazide disodium) Tablets 1.1 g. for the treatment of mild-to-moderate active ulcerative colitis in patients 18 years and older.

In this complete response letter there are no requests for new pre-clinical or clinical trials. The sole issue raised in this letter concerns a deficiency of the manufacturing facility for this application. The manufacturer has responded to the FDA and continues to work with the FDA to resolve the matter. The facility only manufactures COLAZAL^® Capsules and GIAZO™ Tablets for Salix.

Source:

Salix Pharmaceuticals, Ltd.,

Posted in: Medical Condition News | Pharmaceutical News

Comments (0)

Download PDF Copy

Suggested Reading

University of Vienna team develops method to measure molecular charges

CURE GABA-A and Grann Pharmaceuticals announce global partnership to advance rare neurological therapies

Mushrooms deliver nutrition medicine and sustainability solutions in one package

Edible microbeads trap fat to support weight loss

New study reveals long road to seizure control for people with focal epilepsy

WHO expands global network of trusted medical product regulators

Rising liver cancer rates highlight need for urgent action worldwide

Mentavi study validates first fully digital diagnostic pathway for adult ADHD

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.

Post a new comment

(Logout)

Post

Sign in to keep reading

We're committed to providing free access to quality science. By registering and providing insight into your preferences you're joining a community of over 1m science interested individuals and help us to provide you with insightful content whilst keeping our service free.